Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Adiponectin, an adipokine secreted by adipocytes, exerts favorable effects in the milieu of diabetes and metabolic syndrome through its anti-inflammatory, antifibrotic, and antioxidant effects. It mediates fatty acid metabolism by inducing AMP-activated protein kinase (AMPK) phosphorylation and increasing peroxisome proliferative-activated receptor (PPAR)-α expression through adiponectin receptor (AdipoR)1 and AdipoR2, respectively, which in turn activate PPAR gamma coactivator 1 alpha (PGC-1α), increase the phosphorylation of acyl CoA oxidase, and upregulate the uncoupling proteins involved in energy consumption. Moreover, adiponectin potently stimulates ceramidase activity associated with its two receptors and enhances ceramide catabolism and the formation of its anti-apoptotic metabolite, sphingosine 1 phosphate (S1P), independently of AMPK. Low circulating adiponectin levels in obese patients with a risk of insulin resistance, type 2 diabetes, and cardiovascular diseases, and increased adiponectin expression in the state of albuminuria suggest a protective and compensatory role for adiponectin in mitigating further renal injury during the development of overt diabetic kidney disease (DKD). We propose AdipoRon, an orally active synthetic adiponectin receptor agonist as a promising drug for restoration of DKD without inducing systemic adverse effects. Its renoprotective role against lipotoxicity and oxidative stress by enhancing the AMPK/PPARα pathway and ceramidase activity through AdipoRs is revealed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300 · cited 1×
“Therefore, when activated upon ROS exposure, the AMPK-FoxO3a signaling pathway upregulates the expression of silent information regulator T1 (SIRT1), a well-known FoxO3a coactivator, that is thought to mediate apoptotic and autophagy crosstalk [39].”
BackgroundCloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176 · cited 1×
“AdipoR1 and AdipoR2 have seven transmembrane domains and are significantly homologous, sharing 67 % amino acid identity [27], whereas T-cadherin is considered to be an adiponectin-binding protein but its functional significance has not been completely determined.”
BackgroundReceptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
Holland, W. L., Miller, R. A., Wang, Z. V., Sun, K., Barth, B. M., Bui, H. H., Davis, K. E., Bikman, B. T., Halberg, N., Rutkowski, J. M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2277 · Cited by 892 · cited 1×
“Adiponectin modifies the effects of toxic ceramide accumulation by binding to AdipoR1/2, which increases ceramidase activity, catalyzing the conversion of ceramide to sphingosine and subsequently sphingosine-1 phosphate (S1P), independently of AMPK [46].”
BackgroundA small-molecule AdipoR agonist for type 2 diabetes and short life in obesity
Okada-Iwabu, M., Yamauchi, T., Iwabu, M., Honma, T., Hamagami, K.-I., Matsuda, K., Yamaguchi, M., Tanabe, H., Kimura-Someya, T., Shirouzu, M., et al. (2013) · Nature · doi:10.1038/nature12656 · Cited by 757 · cited 2×
“When diabetic mice fed a high-fat diet were treated with AdipoRon, the metabolic improvements, including enhanced glucose and lipid metabolism and insulin sensitivity, were conferred in the liver and skeletal muscle, which ultimately increased their exercise endurance capacity and extended their life span [69].”
BackgroundTsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Combs, T. P., Pajvani, U. B., Berg, A. H., Lin, Y., Jelicks, L. A., Laplante, M., Nawrocki, A. R., Rajala, M. W., Parlow, A. F., Cheeseboro, L., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1068 · Cited by 545 · cited 1×
“Lastly, infertility can be triggered by chronically elevated adiponectin concentrations [66].”
BackgroundSirtuins as potential targets for metabolic syndrome
Guarente, L. (2006) · Nature · doi:10.1038/nature05486 · Cited by 468
Histopathology of Diabetic Nephropathy
Fioretto, P., & Mauer, M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.012 · Cited by 467
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426
Adiponectin signaling and function in insulin target tissues
Ruan, H., & Dong, L. Q. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw014 · Cited by 395 · cited 1×
“The role of adipose tissue or adipocytes as an endocrine organ secreting various adipokines, in particular adiponectin, has come to the forefront in the fight against diabetes and metabolic syndrome because it has been demonstrated to exert pro-metabolic effects through the modulation of glucose and lipid homeostasis…”
BackgroundKim, Y., Lim, J. H., Kim, M. Y., Kim, E. N., Yoon, H. E., Shin, S. J., Choi, B. S., Kim, Y.-S., Chang, Y. S., & Park, C. W. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060627 · Cited by 229
The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease
Stadler, K., Goldberg, I. J., & Susztak, K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0611-8 · Cited by 165
FOXO3A regulates peroxiredoxin III expression in human cardiac fibroblasts
Chiribau, C. B., Cheng, L., Cucoranu, I. C., Yu, Y.-S., Clempus, R. E., & Sorescu, D. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710610200 · Cited by 140 · cited 1×
“The transcriptional activity of the subfamily member FoxO3a is modulated by AMPK in response to metabolic stress to shield quiescent cells from reactive oxygen species (ROS) by antagonizing apoptosis, which reduces oxidative stress by directly increasing the quantity of antioxidant enzymes such as thioredoxin, peroxir…”
BackgroundJensen, T. E., Sylow, L., Rose, A. J., Madsen, A. B., Angin, Y., Maarbjerg, S. J., & Richter, E. A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.07.005 · Cited by 83
Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity
Okada-Iwabu, M., Iwabu, M., Ueki, K., Yamauchi, T., & Kadowaki, T. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.5.363 · Cited by 60 · cited 1×
“Overexpression of the oxidative stress-relieving genes catalase and SOD might have led to the increase in lifespan [70].”
Background
Cited by
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Recinella, L., Orlando, G., Ferrante, C., Chiavaroli, A., Brunetti, L., & Leone, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.578966 · Cited by 261
Hammoud, S. H., AlZaim, I., Al-Dhaheri, Y., Eid, A. H., & El-Yazbi, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.707126 · Cited by 87
Metadata
- Authors
- Kim, Y., & Park, C. W.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-04-10
- Volume
- 20
- Issue
- 7
- Pages
- 1782
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2939561138
- Cited by
- 108
- References
- 16
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.